

## Description of Additional Supplementary Files

**Supplementary Data 1: Mapping statistics and yields for FFPE-CUTAC bead-binding and on-slide protocols.**

**Supplementary Data 2: Summary of significant cCRE differences between FFPE-CUTAC datasets.**

(Related to Figure 4). FDR = False Discovery Rate, which corrects for multiple comparisons, is based on average of normalized counts per base-pair in each cCRE. For each antibody or antibody mixture, replicates were down-sampled and equal numbers of fragments were merged for each genotype. Rank-ordered cCREs for each comparison based on summits are tabulated in Supplementary Table 3.

**Supplementary Data 3\_1: Top RNAPII-Ser5 up-regulated differences between RELA-driven Tumor and normal sections dissected from a single FFPE slide (Related to Figure 6c-d).** FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 3\_2: Top RNAPII-Ser5 down-regulated differences between RELA-driven Tumor and normal sections dissected from a single FFPE slide (Related to Figure 6c-d).** FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 4\_1: Top FFPE-CUTAC hits intersected with RNA-seq data from brain tumors (Related to Figure 8b).** FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 4\_2: Top FFPE-CUTAC hits intersected with RNA-seq data from brain tumors, rank-ordered (Related to Figure 8b).** FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 5\_1: Top hits for YAP1-versus-Normal FDR < 0.05 comparisons (Related to Figure 4d).** FFPE-CUTAC replicates using RNAPII-Ser5p, RNAPII-Ser2,5p, RNAPII-Ser5p + RNAPII-Ser2,5p and H3K27ac from YAP1, PDGFB, RELA and Normal FFPEs were pooled for each antibody/genotype combination (4x4=16) and downsampled to the same level for each antibody or combination. Voom/Limma tumor-versus-normal differences were rank ordered by FDR < 0.05. FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 5\_2: Top hits for PDGFB-versus-Normal FDR < 0.05 comparisons (Related to Figure 4d).** FFPE-CUTAC replicates using RNAPII-Ser5p, RNAPII-Ser2,5p, RNAPII-Ser5p + RNAPII-Ser2,5p and H3K27ac from YAP1, PDGFB, RELA and Normal FFPEs were pooled for each antibody/genotype combination (4x4=16) and downsampled to the same level for each antibody or combination. Voom/Limma tumor-versus-normal differences were rank ordered by FDR < 0.05. FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 5\_3: Top hits for RELA-versus-Normal FDR < 0.05 comparisons (Related to Figure 4d).** FFPE-CUTAC replicates using RNAPII-Ser5p, RNAPII-Ser2,5p, RNAPII-Ser5p + RNAPII-Ser2,5p and H3K27ac from YAP1, PDGFB, RELA and Normal FFPEs were pooled for each antibody/genotype combination (4x4=16) and downsampled to the same level for each antibody or combination. Voom/Limma tumor-versus-normal differences were rank ordered by FDR < 0.05. FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 5\_4: Top hits for YAP1-versus-PDGFB FDR < 0.05 comparisons (Related to Figure 4d).** FFPE-CUTAC replicates using RNAPII-Ser5p, RNAPII-Ser2,5p, RNAPII-Ser5p + RNAPII-Ser2,5p and H3K27ac from YAP1, PDGFB, RELA and Normal FFPEs were pooled for each antibody/genotype combination (4x4=16) and downsampled to the same level for each antibody or combination. Voom/Limma tumor-versus-normal differences were rank ordered by FDR < 0.05. FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 5\_5: Top hits for YAP1-versus-Normal FDR < 0.05 comparisons (Related to Figure 4d).** FFPE-CUTAC replicates using RNAPII-Ser5p, RNAPII-Ser2,5p, RNAPII-Ser5p + RNAPII-Ser2,5p and H3K27ac from YAP1, PDGFB, RELA and Normal FFPEs were pooled for each antibody/genotype combination (4x4=16) and downsampled to the same level for each antibody or combination. Voom/Limma tumor-versus-normal differences were rank ordered by FDR < 0.05. FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 6\_1: Top hits for RELA-versus-Normal FDR < 0.05 comparisons for on-slide FFPE-CUTAC (Related to Figure 6c-d).** FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 6\_2: Top hits for PDGFB-versus-Normal FDR < 0.05 comparisons for on-slide FFPE-CUTAC (Related to Figure 6c-d).** FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 7: Top hits for Tumor-versus-Normal FDR < 0.05 comparisons for liver tumor-versus-normal (Related to Figure 7).** FDR = False Discovery Rate, which corrects for multiple comparisons.

**Supplementary Data 7: Top hits for Tumor-versus-Normal FDR < 0.05 comparisons for liver tumor-versus-normal (Related to Figure 7).**

**Supplementary Data 8\_1: Final Library Structure**

**Supplementary Data 8\_2: Custom Barcodes Adapter 1 (index i5) IDs:** Buenrostro et al. 2015  
<https://doi.org/10.1038/nature14590>

**Supplementary Data 8\_3: Custom Barcodes Adapter 2 (index i7) IDs:** Buenrostro et al. 2015  
<https://doi.org/10.1038/nature14590>